Abstract
The effect of body mass index (BMI) on non-small cell lung cancer (NSCLC) mortality
Journal of clinical oncology, Vol.32(15_suppl), pp.e19041-e19041
05/20/2014
DOI: 10.1200/jco.2014.32.15_suppl.e19041
Abstract
Background: High BMI is associated with increased mortality in many cancers. However, the effect of BMI on survival in NSCLC is less established. In this study, we explored the effect of weight loss prior to diagnosis and BMI at diagnosis, on NSCLC mortality. Methods: This study utilizes the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium database. Clinical and demographic variables and survival measures were obtained from patient surveys and abstracted medical records. BMI at diagnosis was categorized into five groups: <18.5, 18.5–24.9, 25.0–29.9, 30–34.9, and ≥35. Weight loss percentage over the year prior to diagnosis was calculated using the actual weight at diagnosis and the patient recalled weight one year prior to diagnosis. This was categorized into <10% and ≥10% loss of body weight in the year prior to cancer diagnosis. The association of BMI categories with survival was assessed using a log-rank test, and the Cox proportional hazard model was used to model survival adjusting for BMI at diagnosis, weight loss percentage over 1 year prior to NSCLC diagnosis, history of smoking and other variables associated with survival in NSCLC. Results: A total of 2,524 NSCLC patients were included in the analysis. Of these, 45% had a BMI of 18.5-24.9 at diagnosis. Weight loss 1 year prior to diagnosis differed among BMI categories (P <0.0001), with a higher proportion of patients who had a BMI <18.5 at diagnosis and also lost significant weight (≥10% of baseline weight). On univariate survival analysis, patients with BMI ≥35 at diagnosis of NSCLC survived the longest among the other BMI categories (median survival time was 37.5 months (Log Rank Test: P<0.0001). Cox proportional hazard model showed worse survival for patients with BMI <18.5 (HR:1.61, 95% CI: 1.20-2.16) and those who lost ≥10% of their body weight over the year prior to diagnosis (HR:1.45, 95% CI: 1.24-1.71). Conclusions: BMI <18.5 at diagnosis of NSCLC, and loss of ≥10% of body weight in the year prior to diagnosis were associated with increased mortality in all stages of NSCLC. BMI >25, including BMI ≥35, was not associated with increased mortality. Clinical trials are needed to assess if interventions to reverse weight loss and aiming for a higher BMI could prolong survival.
Details
- Title: Subtitle
- The effect of body mass index (BMI) on non-small cell lung cancer (NSCLC) mortality
- Creators
- Taher Abu Hejleh - University of Iowa Hospitals and Clinics, Iowa City, IAElizabeth A Chrischilles - University of Iowa College of Public Health, Iowa City, IAJane F Pendergast - University of Iowa College of Public Health, Iowa City, IAGrelda Yazmin Juarez - Department of Biostatistics, University of Iowa, Iowa City, IARobert B Wallace - University of Iowa College of Public Health, Iowa City, IA
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.32(15_suppl), pp.e19041-e19041
- DOI
- 10.1200/jco.2014.32.15_suppl.e19041
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2014
- Academic Unit
- Pharmacy; Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Biostatistics; Injury Prevention Research Center; Internal Medicine
- Record Identifier
- 9984214663702771
Metrics
18 Record Views